香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號：00270） 以實物分派粤海置地股份的方式支付特別股息已於 2025 年 1 月 21 日完成。 1 粤海投資有限公司 備註： 本公司將按香港《公司條例》 ( 第 622 章 ) 第 662(3) 條及附表 6 第 3 部的規定，將截至 2024 年 12 月 31 日止年度的綜合財務報表適時送呈公司註冊處處長。本公司的核數師已就該等綜合財務報表提交報 告。報告中核數師並無保留意見，亦無提述任何其在無提出保留意見下強調須予注意的事項，也沒 有任何根據香港《公司條例》 ( 第 622 章 ) 第 406(2) 、 407(2) 或 (3) 條的述明。 (3) 此公告為本公司自願性披露，以進一步提升本公司的企業管治水平及透明度。本公司將於往後的財 政年度繼續按季度公佈財務資料。 表現摘要 本集團於本期間的未經審核持續經營業務綜合收入為 46.17 億港元（2024 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 2025年第一季度報告 根 據 上 海 證 券 交 易 所 的 規 定，本 公 司 需 於 第 一 季 度 和 第 三 季 度 刊 發 季 度 報 告。 本季度報告內所載的財務數據均未經審計，並根據中國會計準則而編製。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.09條 及 13.10B條 與 及 證 券 及 期 貨 條 例（香 港 法 例 第571章）第XIVA部項下內幕 消 息 條 文 而 刊 發。 重要提示 – 1 – (1) 華能國際電力股份有限公司（「本公司」、「華能國際」）董 事 會、監 事 會 及 其 董 事、監 事、高 級 管 理 人 員 保 證 季 度 報 告 內 容 的 真 實、準 確、 完 整，不 存 在 虛 假 記 載、誤 導 性 陳 述 或 者 重 大 遺 漏，並 承 擔 個 別 及 連 帶 的 法 ...

| 財務摘要 | 02 | Financial Highlights | | --- | --- | --- | | 五年財務概要 | 03 | Five Year Financial Summary | | 主席報告 | 04 | Chairman's Statement | | 公司資料 | 09 | Corporate Information | | 董事及高級管理人員履歷 | 12 | Profile of Directors and Senior Management | | 管理層討論與分析 | 17 | Management Discussion and Analysis | | 企業管治報告 | 30 | Corporate Governance Report | | 董事會報告 | 52 | Directors' Report | | 獨立核數師報告 | 65 | Independent Auditor's Report | | 綜合損益及其他全面收益表 | 72 | Consolidated Statement of Profit or Loss and Other | | | | Com ...

Financial Performance - The company reported a revenue of HKD 1.2 billion for the fiscal year 2024, representing a year-over-year increase of 15%[6]. - Revenue for 2024 is RMB 2,080.9 million, a decrease of 8.8% compared to RMB 2,282.2 million in 2023[18]. - Gross profit for 2024 is RMB 1,582.7 million, down 6.7% from RMB 1,695.7 million in 2023[18]. - Net profit for 2024 is RMB 175.4 million, an increase of approximately 9.6 times compared to RMB 16.6 million in 2023[18]. - Adjusted operating profit for 2024 is RMB 228.9 million, up 64.9% from RMB 138.8 million in 2023[18]. - The company's gross profit for 2024 was RMB 1,582.7 million, a decrease of 6.7% from RMB 1,695.7 million in 2023, with a gross margin of 76.1%[51]. - Operating profit for 2024 was RMB 192.0 million, significantly up from RMB 33.8 million in 2023, primarily due to improved efficiency in management, R&D, and sales teams[56]. - The company's revenue for the three months ended December 31, 2024, was RMB 563.6 million, a decrease of 10.6% compared to RMB 630.3 million for the same period in 2023[62]. - Revenue from providing talent acquisition and other human resources services to corporate clients was RMB 482.5 million, accounting for 85.6% of total revenue, down 11.9% from RMB 547.9 million in the previous year[63]. User Metrics - The number of registered individual users reached 2.5 million, an increase of 20% compared to the previous year[6]. - The total number of job postings on the platform increased by 35%, indicating a robust demand for recruitment services[6]. - The number of verified corporate users reached 1.43 million, while individual users surpassed 106 million by the end of 2024[23]. - Cumulative registered individual users reached 105.5 million, a year-on-year increase of 11.1%, with monthly active users growing by 5.6%[41]. - Annual paid individual users increased by 20.2% to 123,390 from 102,673 in 2023[32]. - The number of paid enterprise clients decreased by 5.7% to 67,913 from 72,037 in 2023[32]. Strategic Initiatives - The company plans to expand its market presence in Southeast Asia, targeting a 30% growth in user acquisition in the region over the next year[6]. - New product offerings in AI-driven recruitment solutions are expected to launch in Q3 2024, aiming to enhance user engagement by 25%[6]. - A strategic acquisition of a local competitor is anticipated to be completed by the end of Q2 2024, expected to increase market share by 10%[6]. - The company plans to continue enhancing its AI recruitment services and aims for a more agile approach to product innovation in 2025[25]. - The company is focusing on enhancing organizational efficiency and has upgraded its talent management system[34]. - The company aims to optimize recruitment processes through AI-driven insights and candidate matching[30]. Research and Development - The company has allocated HKD 200 million for research and development in 2024, focusing on innovative HR technologies[6]. - The company plans to upgrade its B-end enterprise version to an AI version by March 2025, focusing on AI applications in recruitment[44]. - The AI interview product, Doris, has achieved a scoring consistency of over 95% with senior expert evaluations[22]. - The AI intelligent interviewer "Doris" and the multi-recruitment consultant network (RCN) have gained market recognition, with plans to enhance talent profiling capabilities[45]. Operational Efficiency - The introduction of AI technology in recruitment processes has improved efficiency and reduced costs[35]. - The company aims to improve operational efficiency and talent delivery capabilities within the RCN network through continuous ecosystem development and AI digital assistant empowerment[45]. - The company aims to optimize operational efficiency and enhance product quality to meet diverse customer needs, focusing on personalized services and improving profitability[42]. Financial Management - Cash and cash equivalents as of December 31, 2024, were RMB 810.2 million, up from RMB 666.7 million as of December 31, 2023[79]. - Net cash generated from operating activities for 2024 was RMB 92.5 million, compared to RMB 18.3 million in 2023, primarily due to cost-saving measures and efficiency improvements[80]. - The company's debt-to-equity ratio as of December 31, 2024, was 1.27%, compared to 0.45% as of December 31, 2023[84]. - The company had short-term bank loans totaling RMB 58.0 million as of December 31, 2024, all secured with fixed interest rates ranging from 2.90% to 3.85%[86]. Shareholder Information - A special dividend of HKD 0.42 per share is declared, to be paid on May 8, 2025[18]. - The total comprehensive income attributable to owners of the company for 2024 was RMB 195.1 million, compared to RMB 36.9 million in 2023[78]. - The company has established credit policies to monitor credit risks associated with bank deposits, prepayments, and receivables[92]. - The company recognizes the importance of effective communication with shareholders to strengthen investor relations and ensure transparency in business performance[127]. Compliance and Governance - The company adheres to relevant laws and regulations, including the Companies Ordinance and the Corporate Governance Code, ensuring compliance in its operations[125]. - The company has implemented technology-based measures to protect personal information and comply with applicable privacy laws and regulations[132]. - The company’s independent non-executive directors confirmed their independence as of December 31, 2024, in accordance with the listing rules[145]. - The company has not established any arrangements allowing directors to benefit from purchasing shares or debt securities of the company[156]. Risks and Challenges - Major risks include the inability to improve user experience, adapt to user preferences, and respond to rapid product innovation demands, which could adversely affect business performance[129]. - The company faces various risks, including credit risk, liquidity risk, and currency risk, as detailed in the annual report's financial statements note 29[134]. - The company faces significant risks related to the contractual arrangements, including potential non-compliance with Chinese laws and regulations, which could lead to severe consequences[165]. Talent Management - The company has a performance-based compensation system for its sales team, which includes salary and performance bonuses based on total revenue generated and unique customer retention[195]. - The company's compensation policy is based on individual employee performance and is reviewed regularly[195]. - The remuneration for directors includes director's fees, salaries, housing allowances, and other benefits, with no payments made for joining or leaving the company[196].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 2025年度第一季度報告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.09(2)條及第13.10B 條以及香港法例第571章證券及期貨條例第XIVA項 下 的 內 幕 消 息 條 文 而 作 出。 下文為北京昭衍新藥研究中心股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱 「本集團」）於2025年財政年度的第一季度報告（「2025年度第一季度報告」）。本 公 告 及 隨 附 的 財 務 報 表 最 初 以 中 文 編 製，並 以 中 英 文 版 本 刊 登。如 中 英 文 版 本 出 現 任 何 歧 義 或 衝 ...

目錄 | 公司資料 | 2 | | --- | --- | | 主席報告 | 4 | | 董事及高級管理層的履歷 | 6 | | 管理層討論及分析 | 11 | | 董事會報告 | 16 | | 企業管治報告 | 30 | | 獨立核數師報告 | 48 | | 綜合損益及其他全面收益表 | 54 | | 綜合財務狀況表 | 55 | | 綜合權益變動表 | 57 | | 綜合現金流量表 | 58 | | 綜合財務報表附註 | 59 | | 財務概要 | 111 | 公司資料 董事會 執行董事 Tan Chee Beng先生 （主席兼行政總裁） Tang Ling Ling女士 Tan Wei Leong先生 張錦輝先生 顏建峰先生 獨立非執行董事 Wee Chorng Kien先生 梁又穩先生 梁基偉先生 審計委員會 梁又穩先生 （主席） Wee Chorng Kien先生 梁基偉先生 提名委員會 Tan Chee Beng先生 （主席） Wee Chorng Kien先生 梁基偉先生 薪酬委員會 梁又穩先生 （主席） Tan Chee Beng先生 Tang Ling Ling女士 Wee Chorng K ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性和 完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 安徽皖通高速公路股份有限公司 ANHUI EXPRESSWAY COMPANY LIMITED （於中華人民共和國註冊成立的股份有限公司） （股份編號： 995） 二零二五年第一季度報告 此公告乃根據香港法例第571章證券及期貨條例第XIVA部及香港聯合交易所有 限公司證券上市規則第13.09(2)(a)及13.10B條的規定作出。 根據中華人民共和國（「中國」）上海證券交易所（本公司A股上市的交易所）的適用 規則，安徽皖通高速公路股份有限公司（「本公司」）及其附屬公司（與本公司合稱為 「本集團」）二零二五年第一季度報告（「二零二五年第一季度報告」）將於二零二五年 四月二十九日刊登於國內之報章。隨附將刊登的本公司二零二五年第一季度報告。 二零二五年第一季度報告所載的本集團截至二零二五年三月三十一日止三個月（「報 告期」）之財務資料乃按照中國會計準則編製。中英文版如有歧異，概以中文版為 準。 承董事會命 安 ...

(於開曼群島註冊成立的有限公司) 股份代號:06677.HK 遠洋服務控股有限公司 二零二四年年報 2024年度報告·遠洋服務控股有限公司 目錄 目錄 | 公司概覽 | 4 | 主席報告 | 14 | | --- | --- | --- | --- | | 地理覆蓋範圍 | 6 | 管理層討論與分析 | 18 | | 公司資料 | 8 | 董事及高級管理人員 | 41 | | 財務及運營摘要 | 10 | 投資者關係報告 | 45 | | 年度大事記 | 12 | 可持續發展報告 | 46 | | 獎項與榮譽 | 13 | 董事局報告 | 49 | 002 目錄 2024年度報告·遠洋服務控股有限公司 公司概覽 我們是一家綜合性物業管理服務商，在中國擁有廣闊的地理覆蓋範圍。根據中指研究院的資料，按2024年綜合 實力計，我們榮膺「2024中國物業服務百強企業（第12位）」、「2024中國物業服務百強滿意度領先企業」等多項 榮譽。 122.3 92.5 總合約建築面積 總在管建築面積 百萬平方米 百萬平方米 004 | 企業管治報告 | 68 | 綜合現金流量表 | 99 | | --- | --- | --- ...

Financial Performance - Keymed Biosciences Inc. reported a significant increase in revenue, reaching $50 million for the fiscal year 2024, representing a 25% growth compared to the previous year[10]. - In 2024, the company achieved a sales revenue of approximately RMB 428.12 million, representing a 21% increase compared to RMB 354.10 million in 2023[19]. - The company’s cash and cash equivalents, including time deposits and bank financial products, decreased by 21% to RMB 2.16 billion from RMB 2.72 billion as of December 31, 2023[19]. - The company reported a gross margin of 60%, indicating strong operational efficiency and cost management[17]. - The company reported a pre-tax loss of RMB 508.647 million for 2024, compared to a loss of RMB 356.188 million in 2023, indicating ongoing investment in growth despite losses[81]. - The total assets as of December 31, 2024, were RMB 3.766 billion, a slight decrease from RMB 3.883 billion in 2023[89]. - The company reported a significant increase in user data, with a year-over-year growth of 25% in active users[1]. - Revenue for the last quarter reached $500 million, representing a 15% increase compared to the previous quarter[2]. - The company has reported a significant reduction in bleeding symptoms from 68.2% at baseline to 4.8% at week 8 in the CM313 study[53]. Research and Development - Keymed is advancing its core product CM310, with clinical trials expected to commence in Q2 2025, aiming for FDA approval by the end of 2025[13]. - The R&D budget has been increased by 40%, now totaling $20 million, to accelerate the development of new therapies[16]. - The company aims to enhance its technical platform capabilities to support pipeline development for the next decade, focusing on innovation and patient-centered solutions[17]. - The company has established a comprehensive integrated platform for biopharmaceutical development, covering all key functions from target validation to clinical development[40]. - The company aims to accelerate R&D efficiency through partnerships and licensing arrangements with third parties[41]. - The company has implemented a comprehensive employee training and development program to support employee growth and development[198]. Product Development and Approvals - The first product, Kangyueda (CM310), received approval for three indications, generating total sales revenue of approximately RMB 43 million, with a net sales amount of about RMB 36 million after distributor discounts[21]. - The approval for Sipulizumab injection for the treatment of moderate to severe atopic dermatitis was granted by the National Medical Products Administration in September 2024[22]. - The approval for Sipulizumab injection for chronic rhinosinusitis with nasal polyps was granted in December 2024[23]. - The approval for Sipulizumab injection for seasonal allergic rhinitis is expected in February 2025[24]. - CM310 has received regulatory approval for treating moderate to severe atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis[44]. - The Phase III clinical trial for CM310 demonstrated an EASI-75 response rate of 92.5% at week 52, compared to 88.7% for the placebo group[46]. Strategic Partnerships and Acquisitions - Keymed is exploring strategic acquisitions to enhance its product portfolio, with a budget of $10 million allocated for potential mergers in 2025[15]. - The company established strategic partnerships with several international funds to advance multiple pipeline clinical trials overseas, including a collaboration with OrbiMed for CM512[16]. - An exclusive licensing agreement was established with Timberlyne Therapeutics, granting them global rights (excluding certain regions) to develop and commercialize CM313, with an upfront payment of $30 million and potential additional payments of up to $337.5 million[29]. - The company signed a licensing agreement with Belenos Biosciences for CM512 and CM536, receiving an upfront payment of $15 million and potential additional payments of up to $170 million[58]. Market Expansion and Future Outlook - The company plans to expand its market presence in Asia, targeting a 15% market share in the region by 2026[14]. - Future outlook indicates an expected revenue growth of 20% for the next fiscal year, projecting revenues to reach $60 million[12]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $200 million allocated for potential deals[7]. - New product launches are expected to contribute an additional $100 million in revenue over the next two quarters[4]. Corporate Governance and Management - The board consists of three executive directors, three non-executive directors, and three independent non-executive directors, ensuring a balanced composition with strong independent elements[123]. - The company has implemented a corporate governance code to ensure effective accountability and management structure[120]. - The management team includes experienced professionals with extensive backgrounds in the biopharmaceutical industry, contributing to the company's strategic direction and research management[101][102][105]. - The company has established three committees with specific terms of reference to oversee particular areas of the group's affairs[141]. Environmental, Social, and Governance (ESG) - The company emphasizes the importance of ESG issues and has established a data statistical mechanism for quantifiable key performance indicators as per ESG guidelines[160]. - The company aims to integrate social responsibility and sustainable development concepts into all aspects of its business operations[164]. - The company has committed to strict compliance with laws and regulations, including tax obligations and environmental protection measures[168]. - The ESG report for the year 2024 aims to address the company's responsibilities and respond to key ESG issues of interest to stakeholders[157]. Compliance and Risk Management - The company has implemented a series of internal control policies and procedures to ensure compliance with applicable laws and regulations, including regular employee training[149]. - The company has established a whistleblower protection mechanism to safeguard the identity and rights of whistleblowers[179]. - The compliance management system includes three lines of defense: business departments, compliance and finance departments, and internal audit departments[176]. - The company has not reported any incidents of bribery, fraud, or money laundering during the reporting period[178].

整合資源，創造價值 創造效益 ， 回報社會 年報 2024 Annual Report 2024 年報 Annual Report 2024 Integrate Resources, Create Values, Build Benets And Contribute To The Society | 目錄 | | | --- | --- | | 公司資料 | 2 | | 主席報告書 | 3 | | 管理層討論及分析 | 5 | | 董事及高級管理層履歷資料 | 32 | | 企業管治報告 | 35 | | 董事會報告 | 47 | | 獨立核數師報告 | 60 | | 綜合損益及其他全面收入表 | 64 | | 綜合財務狀況表 | 65 | | 綜合權益變動表 | 67 | | 綜合現金流量表 | 69 | | 綜合財務報表附註 | 71 | | 財務資料概要 | 136 | 公司資料 於2025年3月19日 董事 執行董事： 高明清 （主席兼行政總裁） 高金珠 劉志純 王任翔 獨立非執行董事： 曾偉雄 王志明 王昕 審核委員會 曾偉雄 （主席） 王志明 王昕 薪酬委員會 王志明 （主席） 劉志純 王昕 提 ...